45 results on '"Lingnau, Karen"'
Search Results
2. A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine
3. The novel adjuvant IC31 ® strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice
4. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31
5. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses
6. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects
7. H2-M, a facilitator of MHC class II peptide loading, and its negative modulator H2-O are differentially expressed in response to proinflammatory cytokines
8. A new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses: First in humans
9. Interferon-Regulatory Factor 4 Is Essential for the Developmental Program of T Helper 9 Cells
10. IC31® and IC30, novel types of vaccine adjuvant based on peptide delivery systems
11. Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma
12. Fetal Calf Serum-Free Generation of Functionally Active Murine Dendritic Cells Suitable for In Vivo Therapeutic Approaches
13. Development of a Single-Shot Live-Attenuated Chikungunya Vaccine: A Phase 1 Randomized Clinical Trial in Healthy Adults
14. First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-lived
15. Multikomponenten-Darstellung staubbildender Sternhüllen
16. Novel Vaccine Adjuvants Based on Cationic Peptide Delivery Systems
17. Correction: The Two-Component Adjuvant IC31® Boosts Type I Interferon Production of Human Monocyte-Derived Dendritic Cells via Ligation of Endosomal TLRs
18. The Two-Component Adjuvant IC31® Boosts Type I Interferon Production of Human Monocyte-Derived Dendritic Cells via Ligation of Endosomal TLRs
19. A Novel HIV Vaccine Adjuvanted by IC31 Induces Robust and Persistent Humoral and Cellular Immunity
20. Novel Protein-Based Pneumococcal Vaccines Administered with the Th1-Promoting Adjuvant IC31 Induce Protective Immunity against Pneumococcal Disease in Neonatal Mice
21. Th17/Th1 biased immunity to the pneumococcal proteins PcsB, StkP and PsaA in adults of different age
22. Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection
23. First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-livedMycobacterium tuberculosis-specific Th1-cell like responses
24. Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers
25. Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity
26. Dendritic Cells Require STAT-1 Phosphorylated at Its Transactivating Domain for the Induction of Peptide-Specific CTL
27. Identification of an Indispensable Role for Tyrosine Kinase 2 in CTL-Mediated Tumor Surveillance
28. Adult-Like Anti-Mycobacterial T Cell and In Vivo Dendritic Cell Responses Following Neonatal Immunization with Ag85B-ESAT-6 in the IC31® Adjuvant
29. Unique membrane-interacting properties of the immunostimulatory cationic peptide KLKL5KLK (KLK)
30. The novel adjuvant IC31® strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice
31. Protective anti-mycobacterial T cell responses through exquisitein vivo activation of vaccine-targeted dendritic cells
32. Su.56. Optimization of Schedule, Route and Adjuvant of Therapeutic Peptide Vaccines Against Hcv
33. Poly-l-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines
34. Defined Synthetic Vaccines
35. IL-4 in Combination with TGF-β Favors an Alternative Pathway of Th1 Development Independent of IL-12
36. FCS-free generation of functionally active murine dendritic cells suitable for in vivo therapeutic approaches
37. Unique membrane-interacting properties of the immunostimulatory cationic peptide KLKL5KLK (KLK)
38. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells.
39. Novel Protein-Based Pneumococcal Vaccines Administered with the Th1-Promoting Adjuvant IC31 Induce Protective Immunity against Pneumococcal Disease in Neonatal Mice
40. First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses
41. Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection
42. Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers
43. The novel adjuvant IC31® strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice
44. Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance.
45. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.